ASH 2022

CAR T-Cell

Oral Presentation:  Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT
Description: In this moderated session, researchers will share results of efforts in treating multiple myeloma.
Abstract No. 704
Presenter: Damian Green, M.D.
Saturday, Dec. 10, 4 p.m.

Poster Presentation: Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
Description: We analyzed all patients with MM who received any autologous BCMA CAR-T therapy from January 2017 - June 2022 at our institution (UCSF). Characteristics were compared between older patients (age ≥70 at infusion) and younger patients using Fisher’s & Kruskal-Wallis tests as appropriate. PFS and OS were compared using log-rank tests.
Abstract No. 2236
Presenter: Rahul Banerjee, M.D.
Saturday, Dec. 10, 5:30 p.m.

Poster Presentation: Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
Description: We performed a single-center analysis of all instances of bridging therapy before planned autologous BCMA CAR-T during a 5-year period ending March 2022.
Abstract No. 2286
Presenter: Rahul Banerjee, M.D.
Saturday, Dec. 10, 5:30 p.m.

Poster Presentation: Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Description: Results of 23 B-ALL patients treated with a novel CAR T-cell therapy product using a fully human CD19-targeted scFv (JCAR021).
Abstract No. 3316
Presenter: Alexandre Vinaud Hirayama, M.D.
Sunday, Dec. 11, 6 p.m.

Poster Presentation: Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/Refractory B-ALL 
Description: Results of 23 B-ALL patients treated with a novel CAR T-cell therapy product using a fully human CD19-targeted scFv (JCAR021).
Abstract No. 4653
Presenter: Jordan Gauthier, M.D., M.Sc.
Monday, Dec. 12, 6 p.m.

Poster Presentation: CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study
Description: Results of 23 R/R LBCL patients treated with a first-in-human CAR T-cell therapy product comprising a fully human CD19-targeted scFv (JCAR021)
Abstract No. 4654
Presenter: Nicolas Gazeau, Ph.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation: 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Description: Updated clinical and pharmacologic outcomes from ZUMA-5 after >3 years median follow-up.
Abstract No. 4660
Presenter: David Maloney, M.D., Ph.D.
Monday, Dec. 12, 6 p.m.

Oral Presentation: Therapeutic Targeting of Spliceosome Mutant Myeloid Neoplasms Via PARP1 Inhibition
Description: To identify novel therapeutic targets in SF-mutant myeloid malignancies.
Abstract No. 89
Presenter: Sayantani Sinha, Ph.D.
Saturday, Dec. 10, 10:30 a.m.

Oral Presentation: Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML
Description: Based on compelling preclinical pharmacology observations, Sutro Biopharma evaluated patients on a case-by-case basis for consideration of a single patient IND (compassionate use) program for pediatric patients with CBF/GLIS AML.
Abstract No. 66
Presenter: Soheil Meschinchi, M.D., Ph.D.
Saturday, Dec. 10,  10:45 a.m.

Poster Presentation: Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
Description: We interrogated the genome, transcriptome and associated clinical and laboratory data from the largest cohort of pediatric AML patients to define the prevalence, frequency of co-occurring cytomolecular alterations and outcomes associated with MYC variants.
Abstract No. 722
Presenter: Danielle C. Kirkey, M.D.
Saturday, Dec. 10, 5:30 p.m.

Poster Presentation: Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML
Description: The aims of this phase I/II study are to assess the safety, tolerability and efficacy of lintuzumab-Ac225 in combination with venetoclax in R/R AML.
Abstract No. 1445
Presenter: Johnnie Orozco, M.D., Ph.D.
Saturday, Dec. 10, 5:30 p.m.

Poster Presentation: Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms
Description: We successfully identified: i) distinct QOL trajectories, ii) baseline factors independently associated with QOL trajectories.
Abstract No. 2302
Presenter: Jordan Gauthier, M.D.
Saturday, Dec. 10, 5:30 p.m.

Oral Presentation: Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
Description: We developed a clinical trial for which treatment was assigned based on molecular characteristics and functional drug testing. Patient cell samples were analyzed for 194 recurring mutations and by high throughput screening (HTS) for a custom panel of drugs and drug combinations to comprehensively select the best treatment for each individual patient. We report the final analysis and long-term outcomes of this individualized approach.
Abstract No. 496
Presenter: Pamela Becker, M.D., Ph.D.
Sunday, Dec. 11, 10:15 a.m.

Oral Presentation: Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification
Description: We evaluated whether AHD, therapy-relatedness, or antecedent blood count abnormalities were independently prognostic after accounting for ELN 2022 risk category and TP53 mutation at time of AML presentation.
Abstract No. 597
Presenter: Megan Othus, Ph.D.
Sunday, Dec. 11, 5 p.m.

Oral Presentation: Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
Description: We show that pacritinib is a potent ACVR1 inhibitor with a clinically important impact on TI in patients with MF.
Abstract No. 628
Presenter: Bart Scott, M.D.
Sunday, Dec. 11, 5:15 p.m.

Poster Presentation: Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison
Description: A single-arm phase II trial evaluating dose-adjusted (DA-)EPOCH for adults with ALL demonstrated efficacy and modest toxicity. We compared these outcomes with a retrospective cohort of pts meeting eligibility criteria for the DA-EPOCH trial but received off-study HyperCVAD.
Abstract No. 2694
Presenter: Lucas Zarling, M.D.
Sunday, Dec. 11, 6 p.m.

Poster Presentation: Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
Description: Circulating tumor DNA (ctDNA) may represent a more sensitive and specific method of response assessment. We report updated clinical results with correlation of dynamic ctDNA monitoring as well as data on total metabolic tumor volume (TMTV).
Abstract No. 2913
Presenter: Ryan Lynch, M.D.
Sunday, Dec. 11, 6 p.m.

Poster Presentation: Lithium Attenuates Graft-Versus-Host Disease Via Effects on the Intestinal Stem Cell Niche
Description: Since the current approaches to prevent severe GVHD to date focus on the immune suppression of T cells with calcineurin inhibitors, anti-metabolites or alkylating agents, therapeutic strategies that protect intestinal epithelium from immune injury represents an attractive alternative approach.
Abstract No. 3258
Presenter: Motoko Koyama, M.D., Ph.D.
Sunday, Dec. 11, 6 p.m.

Oral Presentation: Time-Dependent Prediction of Relapse in Patients with Acute Myeloid Leukemia 
Description: Examine the impact of additional initial response variables on relapse or death at various time points up to 3 years, a time point after which AML relapses become very uncommon.
Abstract No. 57
Presenter: John Lim, M.D.
Saturday, Dec. 12, 10 a.m.

Poster Presentation: Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies 
Description: NKTR-255, a novel polymer-conjugated recombinant human interleukin (IL)-15 agonist, maintains the full spectrum of IL-15 biology and provides sustained pharmacodynamic (PD) responses without the need for daily dosing.
Abstract No. 4652
Presenter: Andrew J. Cowan, M.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation: Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
Description: Results of a phase 1/2 study (NCT02728050) evaluating addition of sorafenib to CLAG-M (CLAGM+S) in adults with newly-diagnosed AML or other high-grade myeloid neoplasms (≥10% blasts). Phase 1 results were reported previously.
Abstract No. 4057
Presenter: Anna Halpern, M.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation: Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
Description: To accelerate myeloid cancer therapeutics, the National Clinical Trials Network (NCTN) is launching the National Cancer Institute (NCI) Myeloid Malignancies Molecular Analysis for Therapy Choice (myeloMATCH) precision medicine clinical trial.
Abstract No. 4080
Presenter: Megan Othus, Ph.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation:  Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study
Description: To better understand evolution of the management of secondary AML, we evaluated treatment patterns and outcomes in patients (pts) with primary AML vs secondary AML treated in real-world clinical practice and enrolled in the CONNECT® Myeloid Disease Registry (NCT01688011) by type of site (academic or community/government).
Abstract No. 4023
Presenter: Bart Scott, M.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation: Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income
Description: To identify the interaction between MolResp and other risk factors on mortality and severity in pts with SARS-CoV-2 infection.
Abstract No. 4327
Presenter: Jerald Radich, M.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation: Self-Reported Experiences of Adult Hematopoietic Cell Transplantation Survivors with COVID-19 Vaccination and Infection
Description: Surveyed a long-term HCT survivor population to characterize the use of COVID-19 vaccination, other precautionary measures, and COVID-19 outcomes.
Abstract No. 378
Presenter: Emily Liang, M.D.
Saturday, Dec. 10, 5:15 p.m.

Oral Presentation: Race, Ethnicity and Experienced Racism Are Associated with Adverse Physical and Mental Health Outcomes Among Cancer Survivors
Description: To evaluate associations of race, ethnicity, and experiences of racism, with adverse mental and physical health outcomes in survivors of cancer.
Abstract No. 382
Presenter: H. Joachim Deeg, M.D.
Saturday, Dec. 10, 4:45 p.m.

Poster Presentation: An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Description: Acute myeloid leukemia (AML) has an aggressive course and a historically dismal prognosis. For many patients, hematopoietic stem cell transplantation (HSCT) represents the best option for cure, but access, utilization and health inequities on a global scale remain poorly elucidated.
Abstract No. 3638
Presenter: Molly Tokaz, M.D.
Sunday, Dec. 11, 6 p.m.

Oral Presentation: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Studies Exploring the Immunobiology of HCT
Description: In this moderated session, researchers will share results of efforts using allogeneic transplantation.
Abstract No. 722
Presenter: Kate Markey, M.B., B.S, M.Clin. Res., Ph.D., FRACP
Saturday, Dec. 10, 9:30 a.m.

Oral Presentation: Interleukin 18 Suppresses Regeneration of the Thymus
Description: We identify the inflammatory cytokine interleukin 18 (IL-18) as a novel suppressant of thymic function and propose its targeting to improve immune reconstitution.
Abstract No. 483
Presenter: David Granadier, BS
Monday, Dec. 12, 4:30 p.m.

Poster Presentation: The Zinc-Sensing Receptor GPR39 Is a Master Regulator of Immune Reconstitution after Bone Marrow Transplant in the Thymus and in the Bone Marrow
Description: We show that in addition to its effects in the thymus, modulation of zinc signaling could also profoundly impact on pre-thymic hematopoiesis in the BM.
Abstract No. 4581
Presenter: Lorenzo Lovino M.D., Ph.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation: HSCs Engraft in a Stochastic Pattern and Form Clonal Pools after Transplantation
Description: A single-arm phase II trial evaluating dose-adjusted (DA-)EPOCH for adults with ALL demonstrated efficacy and modest toxicity. We compared these outcomes with a retrospective cohort of pts meeting eligibility criteria for the DA-EPOCH trial but received off-study HyperCVAD.
Abstract No. 2527
Presenter: Stefan Radtke, Ph.D.
Sunday, Dec. 11, 6 p.m.

Oral Presentation: Regulatory T Cell Depletion during Stem Cell Mobilization Enhances Anti-Myeloma Immunity after Experimental Autologous Stem Cell Transplantation
Description: We explored the ability of stem cell mobilization (SCM) to mobilize putative myeloma-specific T cells from the bone marrow (BM) and concurrent effects of regulatory T cell depletion (Treg), hypothesizing that this may represent an opportunity to optimize myeloma-specific immunity prior to ASCT.
Abstract No. 861
Presenter: Shuichiro Takahashi, Ph.D.
Monday, Dec. 12, 3:15 p.m.

Poster Presentation: Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation
Description: We hypothesized that urine-free criteria would yield discordant responses in <10% of patients, a proportion we determined a priori to be clinically irrelevant.
Abstract No. 3529
Presenter: Rahul Banerjee, M.D.
Sunday, Dec. 11, 6 p.m.

Oral Presentation: The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease 
Description: The objectives of this study were to assess the prevalence and predictors of frailty and the effects of frailty on transplant outcomes such as OS and NRM in patients enrolled in the Chronic GVHD Consortium.
Abstract No. 4719
Presenter: Nahid Rashid, M.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation: Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101
Description:  The objectives of this analysis are to compare longitudinal QOL between dUCBT and haplo and to investigate the association of QOL and clinical outcomes.
Abstract No. 4731
Presenter: Stephanie Lee, M.D., M.P.H.
Monday, Dec. 12, 6 p.m.

Poster Presentation: Effects of Severe Acute Graft-Versus-Host Disease on Quality of Life, Medical Comorbidities and Survival
Description: The objectives of this study were to analyze late medical comorbidities, quality of life, non-relapse mortality and survival in patients who recovered from grade III-IV aGVHD.
Abstract No. 4734
Presenter: Nahid Rashid, M.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation: Alternating the Administration of Ixazomib and Lenalidomide As Maintenance Therapy after Autologous Transplant for Multiple Myeloma 
Description: A study to investigate treating with a regimen alternating IMiD lenalidomide with PI ixazomib post ASCT. We report on the toxicity and efficacy of this all-oral maintenance regimen.
Abstract No. 4744
Presenter: Leona Holmberg, M.D., Ph.D.
Monday, Dec. 12, 6 p.m.

Poster Presentation: Prognostic Significance of Chromosomal Genomic Array Testing in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Description: We hypothesized that by correlating CGAT results at the time of diagnosis with key demographic and outcomes data, we can enhance our ability to risk-stratify patients (pts) at the time of diagnosis.
Abstract No. 4145
Presenter: Noam E. Kopmar, M.D.
Monday, Dec. 12, 6 p.m.